Business / Finance

RSS

Repros prices public offering of 2,760,000 shares of common stock

Repros Therapeutics today announced the pricing of its public offering of 690,000 units, consisting of 2,760,000 shares of its common stock, Series A Warrants to purchase 2,070,000 shares of common stock and Series B Warrants to purchase 1,690,500 shares of its common stock, at a price per unit of $17.15.

3 Feb 2011

Nitto Denko announces acquisition of Avecia Biotechnology

Japan's leading diversified materials manufacturer, Nitto Denko Corporation, today announced that it has acquired Avecia Biotechnology, Inc. through Nitto Americas, Inc., a wholly owned subsidiary in Teaneck, New Jersey.

3 Feb 2011

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the fourth quarter of 2010 were GBP 9 million (approximately DKK 77 million).

3 Feb 2011

NeuroMetrix fourth quarter total revenues decrease to $3.1 million

NeuroMetrix, Inc., a science-based health care company transforming patient care through neurotechnology, today reported business and financial highlights for the quarter and year ended December 31, 2010.

3 Feb 2011

Invacare 2010 adjusted earnings per share increase 16% to $1.84

Invacare Corporation today announced its financial results for the quarter and year ended December 31, 2010 and provided guidance for 2011.

3 Feb 2011

Blue Cross and Blue Shield of Minnesota, American Cancer Society receive CEO Cancer Gold Standard accreditation

Blue Cross and Blue Shield of Minnesota and the American Cancer Society - High Plains Division have received CEO Cancer Gold Standard™ accreditation, recognizing the commitment of these organizations to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.

3 Feb 2011

Transcend fourth quarter revenue increases 26% to $26,976,000

TRANSCEND SERVICES, INC., a leading provider of clinical documentation solutions to the U.S. healthcare market, today announced its unaudited financial results for the fourth quarter and year ended December 31, 2010.

3 Feb 2011

CIGNA fourth quarter shareholders' net income increases to $461 million

CIGNA Corporation today reported shareholders' net income of $461 million, or $1.69 per share, for the fourth quarter of 2010 compared with shareholders' net income of $330 million, or $1.19 per share, for the fourth quarter of 2009.

3 Feb 2011

MEDNAX fourth quarter net income increases to $53.8 million

MEDNAX, Inc., the national medical group specializing in neonatal, maternal-fetal, pediatric cardiology, other pediatric subspecialty and anesthesia physician services today reported earnings per share of $1.12 for the three months ended December 31, 2010, that were driven by the Company's successful acquisition efforts throughout the year.

3 Feb 2011

PBOI to leverage revenue cycle management services from NextGen Practice Solutions

NextGen Healthcare Information Systems, a wholly owned subsidiary of Quality Systems, Inc. and leading provider of healthcare information systems and connectivity solutions, today announced that Palm Beach Orthopaedic Institute will leverage revenue cycle management services from NextGen Practice Solutions to optimize its collections and drive business growth.

3 Feb 2011

Angiotech receives letter from TSX to delist its common shares on March 3, 2011

Angiotech Pharmaceuticals, today announced that on February 1, 2011, Angiotech received a letter from the Toronto Stock Exchange stating that Angiotech's common shares will be delisted from the TSX effective at the close of market on March 3, 2011.

3 Feb 2011

Isotechnika closes licensing deal with ILJIN Life Science to advance development of voclosporin

Isotechnika Pharma Inc. is pleased to announce that it has finalized the Development, Distribution and License Agreement with ILJIN Life Science Co., Ltd., previously announced on November 16, 2010. Isotechnika will now receive the license fee of US$4.5 million plus proceeds of US$2.375 million from ILJIN's purchase of its first tranche of Common Shares from treasury.

3 Feb 2011

Ocular Therapeutix closes $14 million Series D financing round

Ocular Therapeutix, Inc. announced today that it has closed a $14 million Series D round of financing. The round was led by Ascension Health Ventures of St. Louis, Missouri, with continued participation by existing investors including Polaris Ventures, SV Life Sciences and Versant Ventures.

3 Feb 2011

Epocrates prices initial public offering at $16.00 per share

Epocrates, Inc. today announced the pricing of the initial public offering of 5,360,000 shares of its common stock at a price to the public of $16.00 per share. The shares are expected to begin trading today on the NASDAQ under the ticker symbol "EPOC." Epocrates is offering 3,574,285 shares and selling stockholders are offering the remaining 1,785,715 shares.

3 Feb 2011

Seattle Genetics prices underwritten public offering of 10,000,000 shares of common stock

Seattle Genetics, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price to the public of $15.50 per share.

3 Feb 2011

Scil Proteins concludes financing round with BioNet Holding for €24 million

Scil Proteins today announced that it has concluded a financing round with its existing investor, BioNet Holding, worth €24 million. The funds are intended to finance the development of two products derived from the Company's Affilin platform into clinical Phase I over the next three years.

2 Feb 2011

Elsevier acquires Cancer Information Group's oncology journals portfolio

Elsevier, the leading global publisher of scientific, technical, and medical information products and services, announced today that it acquired the oncology portfolio of journals previously published by CIG Media Group LP., (operated as Cancer Information Group).

2 Feb 2011

Thermo Fisher Scientific 2010 revenues increase 7% to $10.79 billion

Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2010.

From Thermo Fisher Scientific Inc. 2 Feb 2011

Boston Scientific fourth quarter net sales decrease 4% to $2.002 billion

Boston Scientific Corporation today announced financial results for the fourth quarter and full year ended December 31, 2010, as well as net sales and earnings per share (EPS) guidance for the full year and first quarter 2011.

2 Feb 2011

Boston-based Research 2.0 begins Viral Genetics coverage, publishes initial report

Boston-based Research 2.0 initiated coverage of Viral Genetics, Inc, and published their initial report today. The report is available on the company's website at www.viralgenetics.com/investors/press-releases/R20Report and is also distributed over the internet and through institutional platforms including FactSet, CapitalIQ, and TheMarkets.com.

2 Feb 2011